Drugs / FP-014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06795178 | Jul 2025 → Dec 2027 | prostate cancer | Foresee Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795178 ↗ |
| Route | Subcutaneous | “administered as SC injections” NCT06795178 ↗ |